Bachem Poised to Ride the Peptide Therapeutics Wave, but Execution Is Paramount
Overview
Bachem Holding AG stands as a leading Swiss CDMO, focused on high-value peptide and oligonucleotide APIs, with a business spanning the entire pharmaceutical value chain from R&D to commercial production. Currently, Bachem is at the center of an industry boom, chiefly tied to rapidly expanding demand for peptide-based GLP-1 drugs. To meet this surge, the company is executing a transformative and ambitious expansion program, the success of which is pivotal for future shareholder returns. The market reflects confidence in Bachem’s management, but the high current valuation means flawless delivery on its growth commitments is essential.